DDInter165 DDInter1657
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was later approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use as a treatment for COVID-19 in combination with [remdesivir] under the Emergency Use Authorization (EUA) in November 2020, the FDA fully approved
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with [bortezomib] and [dexamethasone], is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells.[L7117,L7120,L10145] This condition is typically treated with high dose [bortezomib] and [dexamethasone] chemotherapy followed by an autologous stem-cell transplant. Other chemotherapies for multiple myeloma include [lenalidomide] and [dexamethasone], [thalidomide], and may include [melphalan] if the patient is not eligible for transplant. Selinexor was also granted accelerated approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) that have gone through at least 2 lines of systemic therapy. The FDA approved Selinexor in June 2019. The use of selinexor in combination with [bortezomib] and [dexamethasone] was approved by Health Canada in June 2022 for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.
Baricitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Baricitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Flurbiprofen
Baricitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Human adenovirus e serotype 4 strain cl-68578 antigen
Baricitinib {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Baricitinib {u} may lead to a major life threatening interaction when taken with {v} Lurbinectedin
Baricitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Baricitinib may lead to a major life threatening interaction when taken with Idelalisib
Baricitinib may lead to a major life threatening interaction when taken with Lurbinectedin